A5006144681- HIV/AIDS Research and Interventions
- Reproductive tract infections research
- Cervical Cancer and HPV Research
- HIV Research and Treatment
- Adolescent Sexual and Reproductive Health
- Genital Health and Disease
- Reproductive System and Pregnancy
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- Sex work and related issues
- HIV-related health complications and treatments
- Syphilis Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- LGBTQ Health, Identity, and Policy
- Viral-associated cancers and disorders
- Pregnancy and Medication Impact
- Gestational Diabetes Research and Management
- Urinary Tract Infections Management
- Pelvic floor disorders treatments
- Global Cancer Incidence and Screening
- Colorectal and Anal Carcinomas
- Molecular Biology Techniques and Applications
- Reproductive Health and Contraception
- Herpesvirus Infections and Treatments
- Polyomavirus and related diseases
Brown University
2015-2025
Miriam Hospital
2013-2024
John Brown University
2002-2024
Waldorf College
2022-2023
Rhode Island Department of Health
2023
Providence College
2008-2022
Johns Hopkins University Center for AIDS Research
2014-2022
Women's Health Initiative
2019-2022
eHealth Initiative
2019-2022
Providence Center
2021-2022
Human immunodeficiency virus (HIV) infection and related immunosuppression are associated with excess risk for cervical neoplasia human papillomavirus (HPV) persistence. Type-specific HPV was assessed at 6-month intervals HIV-positive HIV-negative women (median follow-up, 2.5 2.9 years, respectively). The type-specific incidence of determined, factors persistence were investigated by statistical methods that accounted repeated measurements. 1.8, 2.1, 2.7 times more likely to have high-,...
To determine which mucosal immunization routes may be optimal for induction of antibodies in the rectum and female genital tract, groups women were immunized a total three times either orally, rectally, or vaginally with cholera vaccine containing killed Vibrio cholerae cells recombinant toxin B (CTB) subunit. Systemic antibody responses assessed at 2-week intervals by quantitation CTB-specific serum secretions collected directly from surfaces oral cavity, rectum, cervix, vagina absorbent...
Abstract A cholera vaccine containing killed vibrios and toxin B subunit (CTB) was used to compare mucosal immunization routes for induction of systemic Ab. Four groups women were given three monthly immunizations by the rectal (Rimm) route, nasal (Nimm) or vaginal route during either follicular (V-FPimm) luteal (V-LPimm) menstrual cycle phase. Nimm performed with 10-fold less determine if administration Ag this can, as in rodents, produce Ab responses comparable those induced higher dose...
A retrospective study was conducted on 134 HIV-infected females evaluated at an HIV/AIDS centre in south India to characterize their socio-demographics, HIV risk factors and initial clinical presentations. The mean age 29 years; 81% were housewives; 95% currently or previously married; 89% reported heterosexual sex as only factor; 88% a history of monogamy. majority reproductive age, thus the potential for vertical transmission devastating impacts families is alarming. Nearly half these...
Background: Human papillomavirus (HPV) type 16 is etiologically associated with approximately half of all cervical cancers. It important, therefore, to determine the characteristics that distinguish HPV16 from other HPV types. A preliminary result based on cross-sectional baseline data in Women's Interagency Immunodeficiency Virus (HIV) Study (WIHS) suggested prevalence might have a weaker association immune status HIV-seropositive women than To address this issue, we examined test results...
Women infected with human immunodeficiency virus (HIV) are disproportionately affected by papillomavirus (HPV)-related anogenital disease, particularly increased immunosuppression. AIDS Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and South Africa to determine immunogenicity safety quadrivalent HPV vaccine 3 strata based on screening CD4 count: >350 (stratum A), 201-350 B), ≤200 cells/µL C). Safety serostatus types 6, 11, 16, 18...
Objective: Few studies have assessed longitudinal genital tract HIV-1 shedding. We determined patterns of RNA shedding over time among women with suppressed plasma viral load (PVL) on antiretroviral treatment. Methods: Paired and were measured every 4 weeks. Participants classified as persistent, intermittent, or nonshedders. Longitudinal analysis examined rates the association PVL, CD4 cell count, infections. Markov transition models used to describe dynamics in using visit-to-visit...
Objective . To evaluate associations between common vaginal infections and human papillomavirus (HPV). Study Design Data from up to 15 visits on 756 HIV-infected women 380 high-risk HIV-uninfected enrolled in the HIV Epidemiology Research (HERS) were evaluated for of bacterial vaginosis, trichomoniasis, Candida colonization with prevalent HPV, incident clearance HPV multivariate analysis. Results Bacterial vaginosis (BV) was associated increased odds (aOR = 1.14, 95% CI: 1.04, 1.26) 1.24,...
We assessed the effect of lower genital tract infections on human immunodeficiency virus type 1 (HIV-1) RNA shedding in female tract. Bacterial vaginosis was significantly associated with HIV-1 expression HIV-infected women.
To determine the frequency of cervicovaginal lavage and plasma HIV-1 RNA levels that are below detectable (< 400 copies/ml) among women on highly active antiretroviral therapy (HAART), non-HAART no therapy. compare effect initiating HAART timing suppression in blood genital tract antiretroviral-naïve women. Data were obtained from 205 HIV-infected with paired viral load measurements. Seven starting had measurements performed daily for one week, at 2 weeks 1 month after Viral quantification...
We examined incidence and correlates of progression regression abnormal cervical cytologic test results, defined as at least low-grade squamous intraepithelial lesions (SILs), in 774 human immunodeficiency virus (HIV)-seropositive 391 HIV-seronegative women monitored semiannually for up to 5.5 years. During follow-up, 224 (35%) HIV-seropositive 34 (9%) had incident SILs detected by Pap test; 47 (7%) developed high-grade lesions. The was 11.5 cases among 2.6 per 100 person-years observation...
We investigated the impact of antimicrobials in cervicovaginal lavage (CVL) from HIV(+) and HIV(-) women on target cell infection with HIV. Since female reproductive tract (FRT) secretions contain a spectrum antimicrobials, we hypothesized that CVL healthy (-) inhibit HIV infection.CVL 32 high CD4 counts 15 were collected by gently washing area 10 ml sterile normal saline. Following centrifugation, anti-HIV activity was determined incubating prior to addition TZM-bl cells. Antimicrobials...
Trappin-2/Elafin is a serine protease inhibitor that plays major role as an anti-inflammatory mediator at mucosal surfaces. In addition, has antibacterial activity against Gram-positive and Gram-negative bacterial fungal pathogens. this study we examined the production of by epithelial cells from human upper lower female reproductive tract well its anti-human immunodeficiency virus (HIV)-1 molecule. We found primary uterine, Fallopian tube, cervical ectocervical produce constitutively...
Human papillomavirus (HPV) infection of the cervix and related abnormal cervical cytology in HIV-infected women has been well described. Little is known about anal HPV women.The SUN Study a prospective cohort study 700 patients including 167 women. At baseline, completed behavioral questionnaire provided, among other samples, swabs for detection genotyping cytologic examination. Here, we present available baseline data on study.Baseline results were 120 (median age: 38 years, 57%...
Abstract Introduction Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) has infected >6 million people worldwide since December 2019. Global reports of HIV/SARS‐CoV‐2 coinfection are limited. To better understand the impact coronavirus disease 2019 (COVID‐19) pandemic on persons with HIV and improve their care, we present an outpatient inpatient clinical experience from Rhode Island, US. Methods We describe preparedness for COVID‐19 pandemic, a case series all known patients at...
Background MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted Phase I clinical trial to assess the safety, pharmacokinetics (PK), ex vivo efficacy of single repeated doses when used intravaginally. Methods findings enrolled healthy reproductive-aged, sexually abstinent women. In Segment A, 9 women received which...
This study was undertaken to assess whether the prevalence of lower genital tract infections among human immunodeficiency virus (HIV)—seropositive women higher than high-risk HIV-seronegative at their baseline visit for HIV Epidemiology Research Study. Results were available 851 HIV-seropositive and 434 women. Human papilloma (HPV) infection more prevalent (64% vs. 28%). Bacterial vaginosis common (35% 33%), followed by trichomoniasis (12% 10%), syphilis (8% 6%), Chlamydia trachomatis (4%...
Objective To assess the variation in HIV-1 over menstrual cycle, including RNA levels female genital tract, plasma HIV-1-RNA levels, CD4 cell counts, and culturable virus. Design A prospective analysis of 55 HIV-1-infected women. Methods Blood tract specimens were collected weekly 8 weeks, spanning two complete cycles. Applying repeated-measures models that used menses as reference level, viral was compared endocervical canal fluid cells (collected by Sno-strips cytobrush, respectively)...
Weck-Cel sponges were examined for suitability as an absorbent material nontraumatic collection of rectal secretions in humans. Sponges tested vitro and determined by quantitative enzyme-linked immunosorbent assay (ELISA) to be capable releasing 100% absorbed albumin all immunoglobulin subtypes after treatment with detergent-supplemented buffer. Protein composition collected from normal women dry (DS) or previously softened moistening saline (MS) was subsequently compared. DS showed evidence...
BufferGel (ReProtect, LLC) is a vaginal gel with an acidic buffering action that was designed to prevent neutralization by semen. The purpose of this study evaluate the safety and tolerability Limited Liability Company) applied vaginally either once or twice daily 27 women who were at low risk for acquisition human immunodeficiency virus (HIV). Participants initially used product 14 days then days; they underwent colposcopy before after exposure. well tolerated, although two-thirds...
To determine the natural history of bacterial vaginosis in women with or at risk for human immunodeficiency virus (HIV).A cohort 854 HIV-infected and 434 HIV-uninfected from four US sites was followed prospectively gynecologic exams every 6 months over a 5-year period. The prevalence, incidence, persistence, severity vaginosis, which defined using Gram-staining scoring system, were calculated generalized estimating equation methods.In adjusted analyses, had higher prevalence than (adjusted...